62019TJ0643_INF
Judgment of the General Court (Third Chamber) of 18 November 2020 –Dermavita v EUIPO – Allergan Holdings France (JUVEDERM ULTRA)
(Case T‑643/19)
(EU trade mark – Revocation proceedings – EU word mark JUVEDERM ULTRA – Genuine use of the mark – Use in connection with the goods in respect of which the mark was registered – Use in the form in which the mark was registered – Use with the proprietor’s consent – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))
1.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Proof of use – Genuine use – Meaning – Criteria for assessment
(Council Regulation No 207/2009, Arts 15(1), first subpara. and 51(1)(a))
(see paras 21, 22)
2.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Word mark JUVEDERM ULTRA
(Council Regulation No 207/2009, Arts 15(1), first subpara. and 51(1)(a))
(see paras 31-33, 40)
3.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Use by a third party with the consent of the trade mark proprietor
(Council Regulation No 207/2009, Art. 15(2)
(see paras 38, 39)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France.
Operative part
The Court:
1.
Dismisses the action;
2.
Orders Dermavita Co. Ltd to bear its own costs and to pay those incurred by the European Union Intellectual Property Office (EUIPO);
3.
Orders Allergan Holdings France to bear its own costs.